UPPSALA SCIENCE PARK, Sweden, Jan. 7, 2002 (PRIMEZONE) -- Gyros AB announced today that its first product, due for launch later this year, will be tested in collaboration with ACE BioSciences at the proteomic company's headquarters in Odense, Denmark.
ACE BioSciences focuses its expertise on functional proteomics and needs to prepare a large number of protein samples per week for analysis by MALDI mass spectrometry, a technique used for protein identification. The new product from Gyros is intended to improve and streamline sample preparation by integrating several steps into a single automated process. Large numbers of samples are prepared in parallel in a microlaboratory in the form of a CD. This industrial approach to sample preparation has so far resulted in a consistent improvement in sensitivity of the final MALDI analyses leading to more reliable identification of even low abundance proteins, a key benefit in proteomic research.
"As in any commercial operation, it is critical that the performance and quality of our products are tested under industrial working conditions," explained Per Sjoeberg, Executive Vice President Commercial Operations at Gyros. "ACE BioSciences fulfils this requirement perfectly and is positioned to give us high quality professional feedback."
Ejvind Mortz, PhD., Chief Executive Officer of ACE BioSciences stated: " As a functional proteomics company in a rapidly growing field, it is essential that we take advantage of the latest tools available to accelerate proteomic research. This collaboration not only gives Gyros an excellent opportunity to fine tune their product, but gives us early access to an exciting technology platform with great potential for adaptation to new applications. We have the chance to be closely involved in the development of products that can give us a strong competitive advantage."
Sjoeberg continued, "We have clearly stated our intention to build up a range of products that enable the expanding proteomics market to benefit from our proprietary technology platform. The interest and enthusiasm of a proteomics company such as ACE BioSciences strongly supports this strategy and we are optimistic that this initial work will lead to new ideas and applications for our technology."
About Gyros AB
Gyros AB offers pharmaceutical, biotechnology and diagnostic companies a unique, proprietary technology platform in which routine or non-routine laboratory processes can be miniaturized and integrated into application- specific CDs. Hundreds of samples can be processed in parallel on these disposable microlaboratories. This new platform brings outstanding gains in efficiency, cost-effectiveness and information content. The ability to integrate different laboratory steps on a single CD offers the potential to reassess and redesign traditional working procedures. The company was founded in 2000 as a spin-off from Amersham Biosciences and currently has more than 80 employees working at its headquarters in Uppsala Science Park, Sweden and in regional sales offices in the USA and UK.
About ACE BioSciences A/S
ACE BioSciences A/S is a biology driven Biotech Company with expertise in functional proteomics. We are building novel three-dimensional Protein Interaction Network databases (PINs) of pathogenic microorganisms. We collaborate with the pharmaceutical and biotechnology industries to use our PINs to identify markers and novel drug targets for human diseases caused by pathogenic microorganisms. ACE BioSciences has to date, established alliances with Micromass, UK, LION bioscience, Germany, the Statens Serum Institute, Copenhagen and the University of Southern Denmark, Odense.
Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Gyros' current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards.
This information was brought to you by Waymaker http://www.waymaker.net.